Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
In malignancies where no universally expressed dominant Ag exists, the use of tumor cell-based vaccines has been proposed. We have modified a mouse neuroblastoma cell line to express either CD80 (B7.1), CD137L (4-1BBL), or both receptors on the tumor cell surface. Vaccines expressing both induce a strong T cell response that is unique in that among responding CD8 T cells, a T effector memory cell (T(EM)) response arises in which a large number of the T(EM) express the alpha-chain of VLA-2, CD49b. We demonstrate using both in vitro and in vivo assays that the CD49b(+) CD8 T cell population is a far more potent antitumor effector cell population than nonfractionated CD8 or CD49b(-) CD8 T cells and that CD49b on vaccine-induced CD8 T cells mediates invasion of a collagen matrix. In in vivo rechallenge studies, CD49b(+) T cells no longer expanded, indicating that CD49b T(EM) expansion is restricted to the initial response to vaccine. To demonstrate a mechanistic link between the expression of costimulatory molecules on the vaccine and CD49b on responding T cells, we stimulated naive T cells in vitro with artificial APC expressing different combinations of anti-CD3, anti-CD28, and CD137L. Although some mRNA encoding CD49b was induced by combining anti-CD3 with anti-CD28 or CD137L, the highest level was induced when all three signals were present. This indicates that CD49b expression results from additive costimulation and that the level of CD49b message serves as an indicator of the effectiveness of T cell activation by a cell-based vaccine.
Yan
Xiaocai
X
Department of Pediatrics, Section of Hematology-Oncology, Medical College of Wisconsin Milwaukee, WI 53226, USA.
Johnson
Bryon D
BD
Orentas
Rimas J
RJ
D053330:4-1BB Ligand / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D002454:Cell Differentiation / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018920:Coculture Techniques; D006801:Humans; D016219:Immunotherapy, Adoptive; D039421:Integrin alpha2 / Q000096:biosynthesis* / Q000235:genetics; D020014:K562 Cells; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008805:Mice, Inbred A; D009447:Neuroblastoma / Q000378:metabolism / Q000517:prevention & control*; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000378:metabolism
D053330:4-1BB Ligand; D019496:Cancer Vaccines; D039421:Integrin alpha2; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9
N Engl J Med. 1999 Oct 14;341(16):1165-73
10519894
J Biol Chem. 1985 Dec 5;260(28):15246-52
2415516
Blood. 2000 Mar 1;95(5):1804-9
10688841
J Biol Chem. 2000 Mar 17;275(11):8255-61
10713152
J Clin Invest. 2000 Mar;105(6):721-9
10727440
J Immunol. 2000 Nov 1;165(9):4935-40
11046019
J Immunol. 2001 Mar 1;166(5):3484-90
11207307
J Biol Chem. 2001 Jun 29;276(26):23518-24
11313353
Eur J Immunol. 2001 May;31(5):1523-30
11465109
J Immunol. 2001 Aug 1;167(3):1313-24
11466348
Cell Immunol. 2001 May 25;210(1):56-65
11485353
J Clin Invest. 2002 Mar;109(5):651-9
11877473
J Immunol. 2002 Oct 15;169(8):4230-6
12370353
J Pediatr Hematol Oncol. 2003 Jan;25(1):8-13
12544767
Cell Immunol. 2003 Mar;222(1):15-26
12798304
Bone Marrow Transplant. 2003 Jul;32(1):103-6
12815485
Eur J Immunol. 2003 Aug;33(8):2133-41
12884287
J Immunol. 2003 Sep 15;171(6):2804-11
12960301
Blood. 2004 Jan 1;103(1):177-84
12969968
Blood. 2004 Mar 15;103(6):2214-20
14645004
Blood. 2004 May 1;103(9):3396-402
14739220
Immunology. 2004 May;112(1):105-16
15096190
J Cell Biol. 1989 Nov;109(5):2455-62
2530239
Proc Natl Acad Sci U S A. 1989 Dec;86(24):9906-10
2557634
Science. 1991 Mar 29;251(5001):1600-2
2011740
Eur J Immunol. 1992 Dec;22(12):3111-9
1446704
Eur J Biochem. 1993 Jul 1;215(1):151-9
8344274
Blood. 2003 Mar 1;101(5):1718-26
12406881
J Biol Chem. 1994 Jan 7;269(1):463-9
8276836
Eur J Immunol. 1994 Sep;24(9):2000-5
7522156
Blood. 1995 Oct 15;86(8):3006-14
7579393
Annu Rev Biochem. 1995;64:403-34
7574488
Eur J Immunol. 1998 Mar;28(3):1116-21
9541607
J Exp Med. 1998 Jun 1;187(11):1849-62
9607925
J Cell Physiol. 1998 Sep;176(3):634-41
9699516
Blood. 1998 Sep 15;92(6):1941-9
9731051
Cell Immunol. 1999 Feb 25;192(1):13-23
10066342
J Immunol. 1999 May 1;162(9):5037-40
10227968
J Immunol. 1999 May 15;162(10):5917-23
10229828
Ann N Y Acad Sci. 2004 Dec;1028:69-80
15650233
J Immunol. 2005 Feb 15;174(4):1898-905
15699116
J Immunother. 2005 Sep-Oct;28(5):449-60
16113601
Eur J Immunol. 2005 Dec;35(12):3673-82
16304637
Inflamm Bowel Dis. 2006 Mar;12(3):172-7
16534417
J Immunol. 2006 Jun 15;176(12):7511-24
16751398
J Immunol. 2006 Jul 15;177(2):968-75
16818752
J Immunother. 2007 Feb-Mar;30(2):203-14
17471167
J Immunother. 2007 Feb-Mar;30(2):227-33
17471169
Lancet. 2007 Jun 23;369(9579):2106-20
17586306
J Immunol. 2007 Oct 1;179(7):4910-8
17878391
J Immunol. 2000 Feb 15;164(4):2009-15
10657652